Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05706909 · ClinicalTrials.gov registry record

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

A clinical trial of Avascular Necrosis and Osteonecrosis, sponsored by The Cleveland Clinic.

Active
Registry status
22
Enrollment target
1
Study location

NCT05706909 is a study of Avascular Necrosis and Osteonecrosis that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 22 participants, below the 294-participant average among 24 other Avascular Necrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05706909, a study of Avascular Necrosis and Osteonecrosis, is active but no longer recruiting, sponsored by The Cleveland Clinic.

ACTIVE NOT RECRUITING
Registry status
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.

Interventions

  • DEVICE Genex with ABMC

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2023-02-08
Est. Completion 2027-07

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT05706909

The ClinicalTrials.gov registry entry for NCT05706909 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 294-participant average among 24 other Avascular Necrosis trials with a reported enrollment target (93% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Avascular Necrosis appearing as the primary indexed condition, and to 1 intervention - of which Genex with ABMC is the first listed.

NCT05706909 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05706909 about?

NCT05706909 is a clinical study titled "The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head". The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.

What is the current status of trial NCT05706909?

This trial is currently active not recruiting. The enrollment target is 22 participants. The study started on 2023-02-08. Estimated completion is 2027-07.

What conditions does trial NCT05706909 study?

This clinical trial studies the following conditions: Avascular Necrosis, Osteonecrosis.

What interventions are being tested in trial NCT05706909?

The interventions under investigation include: Genex with ABMC (DEVICE).

Who is sponsoring clinical trial NCT05706909?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05706909 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Avascular Necrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.